Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance

Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data

(2020) Kyungmin Huh et al.   CLINICAL INFECTIOUS DISEASES

Bloodstream infections in critically ill patients: an expert statement

(2020) Jean-François Timsit et al.   INTENSIVE CARE MEDICINE

In vitro efficacy of Imipenem-Relebactam and Cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae

(2020) L. Tselepis et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase–Producing Enterobacterales During a Regional Outbreak

(2020) Marco Falcone et al.   Open Forum Infectious Diseases

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

(2020) Sara Alosaimy et al.   Open Forum Infectious Diseases

Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales

(2020) Marco Falcone et al.   CLINICAL INFECTIOUS DISEASES

Antimicrobial Resistance in ESKAPE Pathogens

(2020) David M. P. De Oliveira et al.   CLINICAL MICROBIOLOGY REVIEWS

Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination

(2020) Andrea Novelli et al.   Expert Review of Anti-Infective Therapy

Update on the role of ceftazidime-avibactam in the management of carbapenemase-producing Enterobacterales

(2020) Beatriz Dietl et al.   Future Microbiology

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia

(2020) Mercedes Delgado-Valverde et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)

(2020) Matteo Bassetti et al.   Open Forum Infectious Diseases

Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature

(2020) Sandra Zingg et al.   Open Forum Infectious Diseases

Once-Daily Plazomicin for Complicated Urinary Tract Infections

(2019) Florian M.E. Wagenlehner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae

(2019) James A. McKinnell et al.   NEW ENGLAND JOURNAL OF MEDICINE

AmpC β-lactamase-producing Enterobacterales: what a clinician should know

(2019) Simone Meini et al.   INFECTION

DTR, do we need a new definition?

(2019) Roger M Echols et al.   CLINICAL INFECTIOUS DISEASES

Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis

(2019) Matteo Bassetti et al.   ADVANCES IN THERAPY

Comparative Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases from United States Hospitals

(2019) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models

(2019) Rio Nakamura et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical cure rate and cost-effectiveness of carbapenem sparing beta-lactams versus meropenem for Gram-negative infections: a systematic review, meta-analysis, and cost-effectiveness analysis

(2019) Chi Phuong Nguyen et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy

(2019) Laura Escolà-Vergé et al.   Infection and Drug Resistance

Searching for the Optimal Treatment for Metallo- and Serine-β-Lactamase Producing Enterobacteriaceae: Aztreonam in Combination with Ceftazidime-avibactam or Meropenem-vaborbactam

(2019) M Biagi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

(2019) Johann Motsch et al.   CLINICAL INFECTIOUS DISEASES

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

(2019) Marin H Kollef et al.   LANCET INFECTIOUS DISEASES

Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug resistant Pseudomonas aeruginosa : A case report

(2019) Ryan W. Stevens et al.   PHARMACOTHERAPY

Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants

(2019) Pablo Fraile-Ribot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections

(2019) Yohei Doi   CLINICAL INFECTIOUS DISEASES

The Global Ascendency of OXA-48-Type Carbapenemases

(2019) Johann D. D. Pitout et al.   CLINICAL MICROBIOLOGY REVIEWS

Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis

(2019) Adrian Schmid et al.   Scientific Reports

A look at clinical trial design for new antimicrobials for the adult population

(2019) Matteo Bassetti et al.   Expert Review of Clinical Pharmacology

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study

(2019) Matteo Bassetti et al.   Infection and Drug Resistance

Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections

(2019) Maddalena Giannella et al.   Open Forum Infectious Diseases

The role of new β-lactamase inhibitors in gram-negative infections

(2019) Antonio Vena et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Resistance to Ceftazidime-Avibactam and Underlying Mechanisms

(2019) Yuhang Wang et al.   Journal of Global Antimicrobial Resistance

Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Pharmacodynamic Model

(2018) Veronica Rico Caballero et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftolozane-tazobactam against Enterobacter cloacae complex clinical isolates with different β-lactam resistance phenotypes

(2018) Frédéric Robin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OUP accepted manuscript

(2018)   CLINICAL INFECTIOUS DISEASES

Efficacy of Ceftazidime-avibactam Salvage Therapy in Patients with Infections Caused by KPC-producing Klebsiella pneumoniae

(2018) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Ceftolozane/tazobactam: place in therapy

(2018) Daniele Roberto Giacobbe et al.   Expert Review of Anti-Infective Therapy

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets

(2018) Rodrigo E. Mendes et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

(2018) Keith S. Kaye et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme

(2018) James A Karlowsky et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012–15

(2018) Krystyna M Kazmierczak et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15

(2018) Krystyna M Kazmierczak et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

OUP accepted manuscript

(2018)   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Treatment of Infections with OXA-48 producing Enterobacteriaceae

(2018) Adam Stewart et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies

(2018) Zheng Pang et al.   BIOTECHNOLOGY ADVANCES

IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections

(2018) Joseph S Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial

(2018) Dafna Yahav et al.   CLINICAL INFECTIOUS DISEASES

Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa

(2018) Jonathan D Edgeworth et al.   CLINICAL INFECTIOUS DISEASES

Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae

(2018) Elena Carrara et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience

(2018) Matteo Bassetti et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM

(2018) C. De la Calle et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015

(2018) James A. Karlowsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

(2018) Simon Portsmouth et al.   LANCET INFECTIOUS DISEASES

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli , Klebsiella pneumoniae , and Pseudomonas aeruginosa

(2017) Adnan Alatoom et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections

(2017) Matthew Sims et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa

(2017) Marguerite L Monogue et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial

(2017) Joseph Solomkin et al.   JAMA Surgery

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

(2016) Christopher Lucasti et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

(2016) Ryan K. Shields et al.   CLINICAL INFECTIOUS DISEASES

The management of multidrug-resistant Enterobacteriaceae

(2016) Matteo Bassetti et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections

(2016) Matteo Bassetti et al.   Expert Review of Anti-Infective Therapy

Efficacy of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTIs) caused by levofloxacin-resistant pathogens: results from the ASPECT-cUTI trial

(2016) Jennifer A. Huntington et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae : a pooled analysis of Phase 3 clinical trials

(2016) Myra W. Popejoy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

β-Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates

(2015) Rodrigo E. Mendes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

(2015) Joseph Solomkin et al.   CLINICAL INFECTIOUS DISEASES

Multidrug-resistant Gram-negative bacteria: a product of globalization

(2015) P.M. Hawkey   JOURNAL OF HOSPITAL INFECTION

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial

(2015) Patrick NA Harris et al.   Trials

Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study

(2012) Alexis Tabah et al.   INTENSIVE CARE MEDICINE

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

(2011) A.-P. Magiorakos et al.   CLINICAL MICROBIOLOGY AND INFECTION